Newsroom

News from UCLB

Subscribe to our RSS News feed
Fashion designer Sir Paul Smith sponsors Slade student’s final-year project

Fashion designer Sir Paul Smith sponsors Slade student’s final-year project

/ UCLB News
British fashion designer Sir Paul Smith has given a personal donation to support two UCL artists to ‘dress’ the university’s ...
UCLB spinout Senceive wins SME of the Year at The Rail Partnership Awards 2019

UCLB spinout Senceive wins SME of the Year at The Rail Partnership Awards 2019

/ UCLB News
Senceive Ltd, a spinout from the Department of Electronic and Electrical Engineering, has been awarded the SME of the Year ...
Echopoint wins Innovators Award

Echopoint wins Innovators Award

/ UCLB News
Congratulations to UCL spinout Echopoint who received the Innovators Award at last night’s UCL Awards for Innovation & Enterprise 2019 ...
UCL Technology Fund leads £750k investment in Phasecraft

UCL Technology Fund leads £750k investment in Phasecraft

/ UCLB News
Parkwalk and the UCL Technology Fund are leading a £750k investment into Phasecraft, a pioneering quantum computing company, along with ...
NHS England provides online support, developed at UCL, for Type 2 diabetes

NHS England provides online support, developed at UCL, for Type 2 diabetes

/ UCLB News
NHS England (NHSE) has announced that it will offer an online portal to people with type 2 diabetes to help ...
Syncona brings together leading experts in Treg Research for the formation of Quell Therapeutics

Syncona brings together leading experts in Treg Research for the formation of Quell Therapeutics

/ UCLB News
Today Syncona announced the foundation of Quell Therapeutics (Quell), a new cell therapy company, with a £35 million commitment in ...
Using space technology to fight bowel cancer

Using space technology to fight bowel cancer

/ UCLB News
Portico Ventures Programme spinout Odin Vision, which is using space technology to improve the early detection and diagnosis of bowel ...
Annual Review UCLB's 25th Year

Annual Review UCLB’s 25th Year

/ Annual Reports, UCLB News
Download the UCLB Annual Review as a PDF ...
Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019

Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019

/ UCLB News
Conference Call and Webcast to Be Held Tuesday, April 2, 2019 at 8:00 am ET / 1:00 pm BST UCLB ...
SmartTarget software features on CBS News

SmartTarget software features on CBS News

/ Spinout News
 Revolutionary technology developed at UCL Engineering that guides surgeons performing biopsies and improves prostate cancer detection has been featured on ...
Dr Anne Lane appointed as new Managing Director for UCLB

Dr Anne Lane appointed as new Managing Director for UCLB

/ UCLB News
UCLB, the wholly owned subsidiary technology commercialisation company of UCL, has appointed Dr Anne Lane as its new Managing Director ...
LifeArc® launches Technology Transfer Fellowships

LifeArc® launches Technology Transfer Fellowships

/ UCLB News
London, UK, December 17th, 2018.  LifeArc, a leading UK medical research charity, is delighted to launch a new Technology Transfer ...
SmartTarget® technology pinpoints biopsies to detect prostate cancer

SmartTarget® technology pinpoints biopsies to detect prostate cancer

/ UCLB News
Medical software developed at UCL that overlays tumour information from MRI scans onto ultrasound images can help guide surgeons conducting ...
UCL Spinouts Feature in Industrial Strategy Life Sciences Sector Deal Two

UCL Spinouts Feature in Industrial Strategy Life Sciences Sector Deal Two

/ UCLB News
The government has published the second Life Sciences Sector Deal, which outlines public and private sector investments into the sector ...
Freeline Presents Data on AAV-based Gene Therapy for Haemophilia B at the 60th ASH Annual Meeting

Freeline Presents Data on AAV-based Gene Therapy for Haemophilia B at the 60th ASH Annual Meeting

/ UCLB News
A single infusion of FLT180a resulted in sustained mean Factor IX activity of 45%, with no toxicity or adverse effects, ...
Loading...